KR20240099211A9 - Ccr2를 표적으로 하는 항체 - Google Patents

Ccr2를 표적으로 하는 항체

Info

Publication number
KR20240099211A9
KR20240099211A9 KR1020247013799A KR20247013799A KR20240099211A9 KR 20240099211 A9 KR20240099211 A9 KR 20240099211A9 KR 1020247013799 A KR1020247013799 A KR 1020247013799A KR 20247013799 A KR20247013799 A KR 20247013799A KR 20240099211 A9 KR20240099211 A9 KR 20240099211A9
Authority
KR
South Korea
Prior art keywords
antibodies targeting
ccr2
targeting ccr2
antibodies
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247013799A
Other languages
English (en)
Korean (ko)
Other versions
KR20240099211A (ko
Inventor
마티아스 맥
Original Assignee
그라나이트 바이오 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 그라나이트 바이오 아게 filed Critical 그라나이트 바이오 아게
Publication of KR20240099211A publication Critical patent/KR20240099211A/ko
Publication of KR20240099211A9 publication Critical patent/KR20240099211A9/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247013799A 2021-10-27 2022-10-25 Ccr2를 표적으로 하는 항체 Pending KR20240099211A9 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21204904 2021-10-27
EP21204904.3 2021-10-27
PCT/EP2022/079744 WO2023072916A1 (en) 2021-10-27 2022-10-25 Antibodies targeting ccr2

Publications (2)

Publication Number Publication Date
KR20240099211A KR20240099211A (ko) 2024-06-28
KR20240099211A9 true KR20240099211A9 (ko) 2025-12-10

Family

ID=78413745

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247013799A Pending KR20240099211A9 (ko) 2021-10-27 2022-10-25 Ccr2를 표적으로 하는 항체

Country Status (10)

Country Link
US (2) US12168692B1 (https=)
EP (1) EP4423131A1 (https=)
JP (1) JP2024540196A (https=)
KR (1) KR20240099211A9 (https=)
CN (1) CN118159562A (https=)
AU (1) AU2022378899A1 (https=)
CA (1) CA3231124A1 (https=)
IL (1) IL311476A (https=)
MX (1) MX2024004447A (https=)
WO (1) WO2023072916A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024245988A1 (en) * 2023-05-29 2024-12-05 Granite Bio Ag Antibodies targeting ccr2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
DE102006015341A1 (de) 2006-04-03 2007-10-04 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Behandlung von multipler Sklerose und/oder rheumatoider Arthritis
JP5685535B2 (ja) 2008-08-18 2015-03-18 ファイザー インコーポレイティッド Ｃｃｒ２に対する抗体
HK1208236A1 (en) 2012-06-22 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind ccr2
EP2727944A1 (en) * 2012-10-30 2014-05-07 Universitätsklinikum Regensburg Depletion of CCR2-positive monocytes for the treatment of inflammatory conditions in the gastrointestinal system
WO2016079276A1 (en) 2014-11-21 2016-05-26 Takeda Gmbh Use of an anti-gm-csf antagonist and an anti-ccr2 antagonist in the treatment of an infectious disease

Also Published As

Publication number Publication date
US20240392018A1 (en) 2024-11-28
AU2022378899A1 (en) 2024-03-07
MX2024004447A (es) 2024-05-08
KR20240099211A (ko) 2024-06-28
US12168692B1 (en) 2024-12-17
CN118159562A (zh) 2024-06-07
JP2024540196A (ja) 2024-10-31
WO2023072916A1 (en) 2023-05-04
EP4423131A1 (en) 2024-09-04
CA3231124A1 (en) 2023-05-04
IL311476A (en) 2024-05-01
US20250059288A1 (en) 2025-02-20

Similar Documents

Publication Publication Date Title
EP3836960A4 (en) THERAPEUTIC CD47 ANTIBODIES
MA52366A (fr) Anticorps anti-tl1a optimisés
EP3873486A4 (en) Bivalent targeted conjugates
CR20230573A (es) ANTICUERPOS ANTI-SIRP-alfa
LT4192839T (lt) Remdesiviro tarpiniai junginiai
DK4214240T3 (da) Anti-ccr8-antistoffer
EP4061254A4 (en) Targeting guides
EP4081547A4 (en) Novel anti-fgfr2b antibodies
EP4516316A4 (en) TARGETING AGENT
EP4271712A4 (en) ANTI-HVEM ANTIBODIES
IL311043A (en) Anti-il-11rα antibodies
MA56466A (fr) Anticorps anti-epha4
EP4081539A4 (en) Novel anti-fgfr2b antibodies
IL310245A (en) Anti-hla-g antibodies
EP4279508A4 (en) Cd5-targeting fully humanized antibody
MA55132A (fr) Conjugués bi-spécifiques
EP4169952A4 (en) Anti-trop2 antibody
EP4463485A4 (en) Tetrahedral antibodies
EP4414388A4 (en) NEW ANTI-L1CAM ANTIBODY
EP4392455A4 (en) ANTI-CD-25 ANTIBODIES
EP4532558A4 (en) ANTI-ROR1 ANTIBODIES
MA55285A (fr) Anticorps ciblant c5ar
IL292799A (en) Anti-siglec-9 antibody molecules
IL299767A (en) Anti-αlpha-4-βeta-7 antibodies
IL315728A (en) Targeted delivery

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P19 Errors in documents containing ipogçös decisions corrected

Free format text: ST27 STATUS EVENT CODE: A-3-3-P10-P19-OTH-PG1701 (AS PROVIDED BY THE NATIONAL OFFICE)

PG1701 Publication of correction

St.27 status event code: A-3-3-P10-P19-oth-PG1701

Patent document republication publication date: 20251210

Republication note text: Request for Correction Notice (Document Request)

Gazette number: 1020240099211

Gazette reference publication date: 20240628